EPICS Global Perspectives in Lung Cancer
Expert perspectives and strategic insights on the latest therapeutic developments in lung cancer treatment.
Faculty Chair
Corey Langer, MD, FACP
University of Pennsylvania, US
FACULTY MEMBERS
Benjamin Besse, MD, PhD
Institute Gustave Roussy
Villejuif, France
Marina Chiara Garassino, MD
Istituto Nazionale dei Tumori
Milan, Italy
Roy S. Herbst, MD, PhD
Yale Cancer Center
New Haven, CT, US
Solange Peters, MD, PhD
University Hospital of Lausanne
Lausanne, Switzerland
Naiyer Rizvi, MD
Columbia University Irving Medical Center
New York, NY, US
Mark A. Socinski, MD
AdventHealth Cancer Institute
Orlando, FL, US
David Spigel, MD
Sarah Cannon Research Institute
Nashville, TN, US
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
The report that will be produced on the basis of the meeting will discuss the following topics
- Immunotherapy in Stage IV NSCLC
- Immunotherapy in Stage I–III Lung Cancer
- EGFR Mutation-Positive NSCLC (Resectable and Metastatic)
- Targeting Other Gene Mutations (KRAS, HER2, MET [BRAF])
- Targeting Gene Fusions (ALK, ROS1, NTRK [RET])
